In conclusion, we have demonstrated that CD25-biased IL-2cx or IC can synergize with ICIs to mediate complete rejection of established tumors via potent and selective stimulation of CD25+ tumor-specific CD8+ T cells. Here, CD8A is linked to neoplasm.